Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Prevymis

PREVYMIS 240 mg concentrate for solution for infusion PREVYMIS 480 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 43

HOS-139879 · Präparat HOS-098408

(Sum of OATP1B1/3 and/or P-gp inhibition and P-gp/UGT induction) (600 mg once daily ↓ letermovir PO (24 hours after AUC 0.15 (0.13, 0.17) rifampicin))§/ Cmax 0.27 (0.22, 0.31) letermovir (480 mg C24 0.09(0.06, 0.12) once daily PO) (P-gp/UGT induction) Antipsychotics thioridazine Interaction not studied. Thioridazine may decrease plasma Expected: concentrations of letermovir. ↓ letermovir Co-administration of letermovir and thioridazine is not recommended. (P-gp/UGT induction) Endothelin antagonists bosentan Interaction not studied. Bosentan may decrease plasma Expected: concentrations of letermovir. ↓ letermovir Co-administration of letermovir and bosentan is not recommended. (P-gp/UGT induction) Antivirals acyclovir‡ ↔ acyclovir No dose adjustment required. (400 mg single AUC 1.02 (0.87, 1.2) dose)/ letermovir Cmax 0.82 (0.71, 0.93) (480 mg daily) valacyclovir Interaction not studied. No dose adjustment required. Expected: ↔ valacyclovir Herbal products St. John’s wort Interaction not studied. St. John’s wort may decrease plasma (Hypericum Expected: concentrations of letermovir. perforatum) ↓ letermovir Co-administration of letermovir and St. John’s wort is contraindicated. (P-gp/UGT induction) HIV medicinal products efavirenz Interaction not studied. Efavirenz may decrease plasma Expected: concentrations of letermovir. ↓ letermovir Co-administration of letermovir and (P-gp/UGT induction) efavirenz is not recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): thioridazine (HOS-086281) valacyclovir (HOS-139811) efavirenz (HOS-087947) bosentan (HOS-086291) acyclovir (HOS-088527)